|

GDC-4198 Clinical Trials

1 actively recruiting trial across 1 location

No change since August 2026

Also known as: RGT-419B, RO7840734

Pipeline

Phase 1/2: 1

Top Sponsors

  • Genentech, Inc.1

Indications

Tucson, Arizona1 trial

A Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast Cancer

University of Arizona Cancer Center

Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.